DrugDashboards

Anthrasil

Anthrax immune globulin (human) · ANTHRAX IMMUNE GLOBULIN HUMAN 60 [iU]/35mL · Liquid · Intravenous · Emergent BioSolutions Canada Inc.

NDC 60492-0249-02 · 7 VIAL in 1 CARTON / 35 mL in 1 VIAL · BLA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
BLA125562
TE code
Approval date
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Anthrax immune globulin (human) (Liquid)

LabelerStrengthFirst seenLast seen
Emergent BioSolutions Canada Inc.ANTHRAX IMMUNE GLOBULIN HUMAN 60 [iU]/35mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Anthrasil — NDC 60492-0249-02," retrieved September 3, 2026, https://drugdashboards.com/drug/60492024902.

Free to cite with attribution — see how the data is put together.